Saturday 17 October 2026
Export AXSM’s income statement to Excel — free account
Axsome Therapeutics, Inc.
AXSM Healthcare Biotechnology
Axsome Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $638.5 million, up 65.5% from fiscal 2024. In the quarter to June 2026, revenue grew 45.5%, EPS fell 2.06%, free cash flow fell 2.98% and total debt rose 4.66%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
157.14
4.65
−2.87%
Follow AXSM
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
— | — | — | — | — | — | — | — | 5 | 5 |
P/S ratio |
— | — | — | — | — | — | 0.00 | 12.94 | 10.51 | 14.23 |
Altman Z-Score |
— | — | — | — | — | — | 4.86 | 3.38 | 1.58 | 6.91 |
P/FCF ratio |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | — | (6.04) | (2.70) | (6.70) | (5.64) |
P/Operating CF |
— | — | — | — | — | — | (108.15) | (115.29) | (154.72) | (487.10) |
Beneish M-Score |
— | — | — | — | — | — | — | 0.15 | (3.45) | (2.53) |
P/B ratio |
— | — | — | — | — | — | 27.21 | 18.33 | 71.10 | 102.90 |
Price to Tangible BV |
— | — | — | — | — | — | 75.30 | 27.86 | 0.00 | 254.26 |
EV/Sales |
— | — | — | — | — | — | 0.00 | 12.17 | 10.17 | 13.92 |
EV/EBITDA |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | — | — | — | (24.68) | (22.70) | (30.55) | (95.13) |
EV/FCF |
— | — | — | — | — | — | (24.53) | (22.61) | (30.49) | (94.64) |
Quick Ratio |
5.11 | 2.79 | 1.29 | 8.98 | 7.85 | 3.75 | 2.47 | 3.46 | 1.99 | 1.44 |
Current Ratio |
5.30 | 2.90 | 1.41 | 9.00 | 7.85 | 3.75 | 2.54 | 3.63 | 2.11 | 1.55 |
Net Debt/EBITDA |
0.99 | 1.03 | 0.32 | 3.04 | 1.38 | 0.30 | 0.61 | 0.94 | 0.49 | 1.29 |
Debt/Assets |
24.78% | 18.74% | 23.53% | 7.86% | 25.96% | 55.92% | 28.44% | 30.27% | 32.30% | 17.68% |
Debt/Equity |
0.44 | 0.40 | 3.86 | 0.10 | 0.42 | 3.14 | 0.86 | 0.93 | 3.22 | 1.38 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.24 | 0.59 | 0.67 | 1.01 |
Operating CF/Net income |
0.78 | 0.91 | 0.97 | 0.68 | 0.76 | 0.83 | 0.62 | 0.61 | 0.45 | 0.51 |
Capex/Depreciation |
(1.17) | (0.02) | (0.08) | (0.02) | (0.05) | (0.27) | (0.12) | (0.06) | (0.03) | (0.05) |
Interest Coverage |
(208.03) | (20.27) | (29.14) | (54.25) | (38.64) | (21.89) | (24.51) | (35.93) | (42.71) | (25.43) |
| (79.99%) | (151.19%) | (350.78%) | (76.08%) | (70.36%) | (201.51%) | (298.97%) | (159.21%) | (231.63%) | (252.11%) | |
| (62.33%) | (78.47%) | (121.59%) | (57.94%) | (50.60%) | (95.21%) | (89.27%) | (52.02%) | (49.66%) | (29.11%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (3,779.83%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(87.95%) | (124.80%) | (696.64%) | (34.89%) | (64.06%) | (204.60%) | (124.92%) | (65.32%) | (112.39%) | (86.93%) |
Average Days of Receivables |
— | — | — | — | — | — | 275.00 | 127.90 | 134.38 | 128.32 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 115.81% | 36.20% | 48.50% | 28.70% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 318.27% | 119.41% | 106.65% | 89.37% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.21 | 0.11 | 0.10 | 0.08 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 75.40% | 23.14% | 22.09% | 14.68% |
Graham Net Nets |
— | — | — | — | — | — | 0.01 | 0.03 | (0.01) | 0.00 |
Graham Number |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | — | — | — | — | (6.23%) | (6.75%) | (7.08%) | (2.02%) |
Free Cash Flow Yield |
— | — | — | — | — | — | (3.93%) | (4.16%) | (3.17%) | (1.03%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.23 | 5.96 | 8.05 | 12.83 |
Operating CF per Share |
(1.11) | (1.16) | (1.12) | (1.36) | (2.11) | (2.88) | (2.87) | (3.19) | (2.68) | (1.88) |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | 0.00 | (0.01) | (0.02) | (0.01) | (0.01) | (0.01) |
Free Cash Flow per Share |
(1.12) | (1.16) | (1.12) | (1.36) | (2.11) | (2.89) | (2.88) | (3.21) | (2.69) | (1.89) |
Cash per Share |
1.91 | 1.49 | 0.52 | 6.47 | 4.94 | 2.30 | 4.94 | 8.50 | 6.58 | 6.49 |
Shareholders Equity per Share |
1.13 | 0.73 | 0.03 | 5.25 | 3.06 | 0.42 | 2.69 | 4.20 | 1.19 | 1.77 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.13 | 0.73 | 0.03 | 5.25 | 3.06 | 0.42 | 2.69 | 4.20 | 1.19 | 1.77 |
Free Cash Flow |
(21.39) | (26.48) | (30.09) | (46.39) | (78.50) | (108.53) | (117.21) | (145.66) | (128.68) | (93.88) |
Working Capital |
30.83 | 23.12 | 4.39 | 195.88 | 160.59 | 63.45 | 149.08 | 365.41 | 254.96 | 210.15 |
Capital Expenditures |
(0.10) | (0.01) | (0.03) | (0.02) | (0.05) | (0.31) | (0.70) | (0.58) | (0.27) | (0.48) |
Net Current Asset Value |
21.36 | 16.46 | 0.77 | 178.55 | 111.68 | 14.36 | 23.72 | 107.00 | (26.42) | (12.52) |
EV/EBIT |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.89 | 7.53 | 8.20 | 22.46 | 16.44 | 4.06 | 8.15 | 11.12 | 18.15 | 18.45 |
Cash ROIC |
(31.61%) | (46.13%) | (162.40%) | (11.15%) | (22.69%) | (71.79%) | (28.97%) | (19.29%) | (23.14%) | (17.61%) |
Accounts Receivable Turnover |
— | — | — | — | — | — | 0.00 | 4.08 | 3.26 | 3.48 |
Accounts Payable Turnover |
0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.09 | 0.20 | 0.66 | 0.59 | 0.69 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.68 | 2.16 | 2.17 |
Average Days of Payables |
72,665.27 | 29,435.62 | 27,522.05 | 107,085.91 | 63,435.78 | 4,152.89 | 2,710.82 | 569.65 | 789.09 | 503.83 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 303.35 | 211.94 | 172.42 | 214.78 |
Average Receivables |
— | — | — | — | — | — | — | 66.26 | 118.41 | 183.23 |
Average Payables |
2.99 | 3.76 | 3.56 | 7.32 | 12.22 | 13.33 | 25.88 | 39.64 | 56.34 | 68.77 |
Average Inventory |
— | — | — | — | — | — | — | 9.73 | 15.43 | 21.84 |
Average Assets |
43.64 | 36.88 | 25.47 | 117.96 | 203.34 | 136.96 | 209.63 | 459.86 | 578.37 | 629.15 |
Average Common Equity |
34.01 | 19.14 | 8.83 | 89.83 | 146.26 | 64.71 | 62.59 | 150.27 | 124.00 | 72.65 |
Columns are period end dates